Apr. 22 at 8:42 PM
$CRBP Am I missing something? The FDA looked at the oncology data and determined that a fast track to AA is possible via relatively small, inexpensive trials in two indications. A viable P3 candidate in its class should be worth
$500M-
$1B depending on the strength of the data. There's some overhang from the licensing deal, but nothing known to be disqualifying. The obesity drug looks even better and could be worth multiple billions. It's an update on a blockbuster pulled due to psychiatric side-effects, but none appeared in the early data and the current trial hasn't been stopped despite screening for similar problems. Yet the company trades barely above cash value. It looks like market inefficiency to me, but I'm open to other views.
